EXHIBIT 2012
`
`EXHIBIT 2012
`
`
`
`

`
`Case 1:14-cv-01332-UNA Document 4 Filed 10/21/14 Page 1 of 1 PagelD #: 148
`
`AO 120 (Rev. 08/10
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`on the following
`District of Delaware
`filed in the U.S. District Court
`QJ Patents. ( q the patent action involves 35 U.S.C. § 292.):
`q Trademarks or (cid:9)
`
`DOCKET NO.
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`DATE FILED
`10/21/2014
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`District of Delaware
`
`WOCKHARDT BIO LTD., WOCKHARDT LTD., and
`WOCKHARDT USA, LLC
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 (cid:9) US 8,445,524 B2
`
`2 US 8,436,190 B2
`
`3 US 8,609,863 B2
`
`4 US 8,791,270 B2
`
`5
`
`5/21/2013
`
`5/7/2013
`
`Cephalon, Inc.
`
`Cephalon, Inc.
`
`12/17/2013
`
`Cephalon, Inc.
`
`7/29/2014
`
`Cephalon, Inc.
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`n Amendment (cid:9)
`DATE OF PATENT
`OR TRADEMARK
`
`n Answer (cid:9)
`
`n Cross Bill (cid:9)
`
`n Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0001
`
`CEPHALON, INC. -- EXHIBIT 2012 0001
`
`(cid:9)
`(cid:9)
`

`
`Case 1:14-cv-01117-GMS Document 10 Filed 10/03/14 Page 1 of 3 PagelD #: 151
`Case 1:14-cv-01117-GMS Document 4 Filed 09/02/14 Page 1 of 1 PagelD #: 144
`
`AO 120 (Rev. 08/10
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`on the following
`District of Delaware (cid:9)
`filed in the U.S. District Court (cid:9)
`El Trademarks or (cid:9)
`RI Patents. ( 0 the patent action involves 35 U.S.C. § 292.):
`DOCKET NO.
`
`District of Delaware
`
`DATE FILED
`9/2/2014
`
`U.S. DISTRICT COURT
`
`PLAINTIFF
`CEPHALON, INC.
`
`DEFENDANT
`NANG KUANG PHARMACEUTICAL CO., LTD. and
`CANDA NK-1, LLC
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 US 8,445,524 B2
`
`2 US 8,436,190 B2
`
`5/21/2013
`
`5/7/2013
`
`Cephalon, Inc.
`
`Cephalon, Inc.
`
`3 US 8,609,863 B2
`
`12/17/2013
`
`Cephalon, Inc.
`
`4 US 8,791,270 B2
`
`7/29/2014
`
`Cephalon, Inc.
`
`5
`
`DATE INCLUDED
`
`PATENT OR
`TRADEMARK NO.
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`II Amendment (cid:9)
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer (cid:9)
`
`• Cross Bill (cid:9)
`
`0 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`(NA ; (cid:9)
`
`06-1khr15 (cid:9)
`
`""j.e.12.
`
`CLERK United States District Court
`United
`844 N. King Street, Unit 18
`... (cid:9)
`rn- 4 nr1414
`ko a.
`
`(BY) DEPUJER1.7„:.*4 (cid:9)
`
`DATE
`
`,
`
`-
`
`N/3/M
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0002
`
`CEPHALON, INC. -- EXHIBIT 2012 0002
`
`(cid:9)
`

`
`Case 1:13-cv-02095-GMS Document 29 Filed 09/18/14 Page 1 of 1 PagelD #: 454
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`for the District of Delaware (cid:9)
`on the following
`filed in the U.S. District Court (cid:9)
`12( Patents. ( q the patent action involves 35 U.S.C. § 292.):
`q Trademarks or (cid:9)
`
`DOCKET NO.
`13-2095-GMS
`PLAINTIFF
`
`CEPHALON, INC.
`
`DATE FILED
`9/18/2014
`
`U.S. DISTRICT COURT
`for the District of Delaware
`
`DEFENDANT
`ACCORD HEALTHCARE, INC. and INTAS
`PHARMACEUTICALS LTD.
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 8,445,524
`
`2 8,436,190
`
`3 8,609,863
`
`4
`
`5
`
`5/21/2013
`
`5/7/2013
`
`CEPHALON, INC.
`
`CEPHALON, INC.
`
`12/17/2013
`
`CEPHALON, INC.
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENT OR
`TRADEMARK NO.
`
`INCLUDED BY
`
`[4 Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`n Answer (cid:9)
`
`n Cross Bill (cid:9)
`
`n Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 8,791,270
`
`7/29/2014
`
`CEPHALON, INC.
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0003
`
`CEPHALON, INC. -- EXHIBIT 2012 0003
`
`

`
`Case 1:14-cv-01116-UNA Document 4 Filed 09/02/14 Page 1 of 1 PagelD #: 149
`
`AO 120 (Rev. 08/10
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`District of Delaware (cid:9)
`on the following
`filed in the U.S. District Court (cid:9)
`RI Patents. ( q the patent action involves 35 U.S.C. § 292.):
`q Trademarks or (cid:9)
`
`DOCKET NO.
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`DATE FILED
`9/2/2014
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`District of Delaware
`
`SAGENT PHARMACEUTICALS, INC. and
`SAGENT AGILA LLC
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I (cid:9) US 8,445,524 B2
`
`5/21/2013
`
`Cephalon, Inc.
`
`2 US 8,436,190 B2
`
`5/7/2013
`
`Cephalon, Inc.
`
`3 US 8,609,863 B2
`
`12/17/2013
`
`Cephalon, Inc.
`
`4 US 8,791,270 B2
`
`7/29/2014
`
`Cephalon, Inc.
`
`5
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`n Amendment (cid:9)
`DATE OF PATENT
`OR TRADEMARK
`
`n Answer (cid:9)
`
`n Cross Bill (cid:9)
`
`n Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above (cid:9)
`
`entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0004
`
`CEPHALON, INC. -- EXHIBIT 2012 0004
`
`

`
`Case 1:14-cv-00671-UNA Document 5 Filed 05/27/14 Page 1 of 1 PagelD #: 112
`
`AO 120 (Rev. 08/10
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`District of Delaware (cid:9)
`on the following
`filed in the U.S. District Court (cid:9)
`q Trademarks or (cid:9) g Patents. ( q the patent action involves 35 U.S.C. § 292.):
`U.S. DISTRICT COURT
`DATE FILED
`DOCKET NO.
`5/27/2014
`
`District of Delaware
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`DEFENDANT
`
`BRECKENRIDGE PHARMACEUTICAL, INC.
`and NATCO PHARMA LTD.
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 (cid:9) US 8,445,524 B2
`
`2 US 8,436,190 B2
`
`5/21/2013
`
`5/7/2013
`
`Cephalon, Inc.
`
`Cephalon, Inc.
`
`3 US 8,609,863 B2
`
`12/17/2013
`
`Cephalon, Inc.
`
`4
`
`5
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`n Amendment (cid:9)
`DATE OF PATENT
`OR TRADEMARK
`
`n Answer (cid:9)
`
`n Cross Bill (cid:9)
`
`n Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0005
`
`CEPHALON, INC. -- EXHIBIT 2012 0005
`
`

`
`Case 1:13-cv-02095-GMS Document 15 Filed 04/09/14 Page 1 of 1 PagelD #: 224
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`on the following
`for the District of Delaware (cid:9)
`filed in the U.S. District Court (cid:9)
`Gif Patents. ( 0 the patent action involves 35 U.S.C. § 292.):
`0 Trademarks or (cid:9)
`
`DOCKET NO.
`13-2095-GMS
`PLAINTIFF
`CEPHALON, INC.
`
`1DATE FILED
`12/26/2013
`
`1U.S. DISTRICT COURT
`for the District of Delaware
`
`DEFENDANT
`ACCORD HEALTHCARE, INC. and INTAS
`PHARMACEUTICALS LTD.
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`5/21/2013
`
`5/7/2013
`
`CEPHALON, INC.
`
`CEPHALON, INC.
`
`1 8,445,524
`
`2 8,436,190
`
`3
`
`4
`
`5
`
`following patent(s)/ trademark(s) have been included:
`
`DATE INW.J261)4
`
`PATENT OR
`TRADEMARK NO.
`
`1 8,609,863
`
`INCLUDED BY
`
`Ei Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer (cid:9)
`
`• Cross Bill (cid:9)
`
`• Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`12/17/2013
`
`CEPHALON, INC.
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`I
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0006
`
`CEPHALON, INC. -- EXHIBIT 2012 0006
`
`

`
`Case 1:14-cv-00333-UNA Document 4 Filed 03/14/14 Page 1 of 1 PagelD #: 45
`
`AO 120 (Rev. 08/10
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`on the following
`for the District of Delaware (cid:9)
`filed in the U.S. District Court (cid:9)
`'Patents. ( q the patent action involves 35 U.S.C. § 292.):
`1=1Trademarks or (cid:9)
`
`DOCKET NO.
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`DATE FILED
`3/14/2014
`
`U.S. DISTRICT COURT
`for the District of Delaware
`
`DEFENDANT
`
`SUN PHARMA GLOBAL FZE, SUN PHARMACEUTICAL
`INDUSTRIES LTD., and SUN PHARMACEUTICAL
`INDUSTRIES, INC.
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 (cid:9) US 8,609,863 B2
`
`12/17/2013
`
`Cephalon, Inc.
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`q Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`q Answer (cid:9)
`
`n Cross Bill (cid:9) q Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0007
`
`CEPHALON, INC. -- EXHIBIT 2012 0007
`
`

`
`Case 1:14-cv-00334-UNA Document 4 Filed 03/14/14 Page 1 of 1 PagelD #: 44
`
`AO 120 (Rev. 08/10
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`on the following
`for the District of Delaware (cid:9)
`filed in the U.S. District Court (cid:9)
`Rf Patents. ( q the patent action involves 35 U.S.C. § 292.):
`q Trademarks or (cid:9)
`
`DOCKET NO.
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`DATE FILED
`3/14/2014
`
`U.S. DISTRICT COURT
`for the District of Delaware
`
`DEFENDANT
`
`DR. REDDY'S LABORATORIES, LTD. and DR.
`REDDY'S LABORATORIES, INC.
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 (cid:9) US 8,609,863 B2
`
`12/17/2013
`
`Cephalon, Inc.
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`n Amendment (cid:9)
`DATE OF PATENT
`OR TRADEMARK
`
`n Answer (cid:9)
`
`n Cross Bill (cid:9)
`
`n Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0008
`
`CEPHALON, INC. -- EXHIBIT 2012 0008
`
`

`
`UNITED STA (cid:9)1ES PA1ENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO. (cid:9)
`
`13/719,379
`
`ISSUE DATE
`
`12/17/2013
`
`PATENT NO. (cid:9)
`
`ATTORNEY DOCKET NO. (cid:9)
`
`CONFIRMATION NO.
`
`8609863
`
`CEPH-4457/CP391B US
`
`6187
`
`11/26/2013
`7590
`46347 (cid:9)
`WOODCOCK WASHBURN LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):
`
`Jason Edward Brittain, El Cajon, CA;
`Joe Craig Franklin, Tulsa, OK;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about why the USA is the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`IR103 (Rev. 10/09)
`
`0009
`
`CEPHALON, INC. -- EXHIBIT 2012 0009
`
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`

`
`Receipt date: 06/03/2013
`
`1 371 9379 - GAU: 1617
`
`Substitute for 1449/PTO
`
`Complete if Known
`Application Number
`13/719,379
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`Filing Date
`
`December 19, 2012
`
`First Named Inventor
`
`Jason Edward Brittain
`
`Art Unit
`
`1617
`
`(use as many sheets as necessary)
`
`Sheet (cid:9)
`
`1 (cid:9)
`
`of (cid:9)
`
`1
`
`Examiner Name
`
`Soroush, All
`Attorney Docket Number CEPH-4457 / CP391B US
`
`U. S. PATENT APPLICATION DOCUMENTS
`
`Examiner
`Initials
`
`Cite
`No.
`
`Application Number
`
`Fling Date
`MM-DD-YYYY
`
`Name of Patentee or Applicant of Cited Document
`
`IA,S./
`
`116
`
`13/719,409
`
`12-19-2012
`
`Cephalon, Inc.
`
`Ch
`arlf41L?P°Iitile
`No.
`
`Document, to
`
`U. S. PUBLICATION AND PATENT DOCUMENTS
`Publication or
`Grant Date
`MM-DD-YYYY
`
`Name of Patentee or Applicant of Cited Document
`
`Document Number
`
`Number - Kind Code (if known)
`
`J.WZ./
`
`117
`
`2013/0041003 Al
`
`02-14-2013
`
`CcN (cid:9)
`
`, (cid:9)
`
`• (cid:9)
`
`brittain; Jason Edward ; (cid:9) et al
`
`"1 548,1,i 5 118
`
`8,436,190
`
`05-07-2013
`
`Brittain, J.E. et al.
`
`NON PATENT LITERATURE DOCUMENTS
`
`Examiner
`Initials
`
`Cite
`No.
`
`Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial,
`symposium, catalog, etc.), date, page(s), Volume-issue Number(s), publisher, city and/or country where published.
`
`T
`
`1A.S,/
`
`119
`
`Teagarden et al., "Practical aspects of lyophilization using non-aqueous co-solvent
`systems," European Journal of Pharmaceutical Sciences, March 2002, 15(2), 115-133
`
`/A.S,/
`
`120
`
`Wittaya-Areekul et al., "Freeze-drying of tert-butyl alcohol/water cosolvent systems: Effects
`of formulation and process variables on residual solvents," Journal of Pharmaceutical
`Sciences, April 1998, 87(4), 491-495
`
`Examiner
`Signature
`
`/Ali Sorntish;
`
`Date
`Considered
`
`09/18/2013
`
`0010
`
`CEPHALON, INC. -- EXHIBIT 2012 0010
`
`(cid:9)
`

`
`Receipt date: 01/28/2013
`
`1 371 9379 - GAU: 1617
`
`Substitute for 1449/PTO
`
`Complete if Known
`Application Number
`13/719,379
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`Filing Date
`
`December 19, 2012
`
`First Named Inventor
`
`Jason Edward Brittain
`
`Art Unit
`
`1629
`
`(use as many sheets as necessary)
`
`Sheet (cid:9)
`
`2 (cid:9)
`
`of (cid:9)
`
`7
`
`Examiner Name
`
`Not Yet Assigned
`Attorney Docket Number CEPH-4457 / CP391B US
`
`Examiner
`Initials
`
`Cite
`No.
`
`U. S. PUBLICATION AND PATENT DOCUMENTS
`Publication or
`Grant Date
`MM-DD-YYYY
`
`Name of Patentee or Applicant of Cited Document
`
`Document Number
`
`Number - Kind Code (if known)
`
`/A.S./
`
`25
`
`26
`
`27
`
`28
`
`29
`
`30
`
`31
`
`32
`
`5,192,743
`
`5,204,335
`
`5,227,373
`
`5,227,374
`
`5,268,368
`
`5,413,995
`
`5,418,223
`
`5,750,131
`
`5,770,230
`
`03-09-1993
`
`Hsu et al.
`
`04-20-1993
`
`Sauerbier et al.
`
`07-13-1993
`
`Alexander et al.
`
`07-13-1993
`
`Alexander et al.
`
`12-07-1993
`
`Palepu
`
`05-09-1995
`
`Alexander et al.
`
`05-23-1995
`
`Palepu et al.
`
`05-12-1998 Wichert et al.
`
`06-23-1998
`
`Teagarden et al.
`
`,37
`,
`applied
`38
`
`Qian
`
`(s ;e
`ume it,
`
`to do
`/C .0
`b./
`/2o 3
`I 1/2
`
`33
`
`34
`
`35
`
`36
`
`39
`
`40
`
`41
`
`42
`
`43
`
`44
`
`45
`V 46
`
`5,776,456
`
`5,955,504
`
`5,972,912
`
`6,034,256
`
`6,077,850
`
`6,090,365
`
`6,271,253
`
`6,380,210
`
`6,492,390
`
`6,545,034
`
`6,569,402
`
`6,573,292
`
`6,613,927
`
`07-07-1998
`
`Anderson et al.
`
`09-21-1999 Wechter et al.
`
`10-26-1999
`
`Marek et al.
`
`03-07-2000
`
`06-20-2000
`
`4111-' (cid:9)
`
``-• (cid:9)
``-• (cid:9)
`.,rfcr (cid:9)
`
`Carter et al.
`
`Carter et al.
`
`07-18-2000
`
`Kaminski et al.
`
`08-07-2001
`
`Carter et al.
`
`04-30-2002
`
`Desimone et al.
`
`12-12-2002
`
`41,1a3fcrrcr (cid:9)
`
`Carter et al.
`
`04-08-2003
`
`Carson et al.
`
`05-27-2003
`
`Cheesman et al.
`
`06-03-2003
`
`Nardella
`
`09-02-2003
`
`Kwok
`
`Examiner
`Signature
`
`Ii i Sorousft'
`
`Date
`Considered
`
`02125/2013
`
`0011
`
`CEPHALON, INC. -- EXHIBIT 2012 0011
`
`(cid:9)
`

`
`UNITED STA (cid:9)I ES PA (cid:9)PENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO. (cid:9)
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO. (cid:9)
`
`CONFIRMATION NO.
`
`13/719,379
`
`12/19/2012
`
`Jason Edward Brittain
`
`CEPH-4457/CP391B US
`
`6187
`
`46347 (cid:9)
`7590 (cid:9)
`11/18/2013
`WOODCOCK WASHBURN LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`EXAMINER
`
`SOROUSH, ALI
`
`ART UNIT
`
`PAPER NUMBER
`
`1617
`
`NOTIFICATION DATE
`
`DELIVERY MODE
`
`11/18/2013
`
`ELECTRONIC
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the
`following e-mail address(es):
`eofficemonitor@woodcock.com
`
`PTOL-90A (Rev. 04/07)
`
`0012
`
`CEPHALON, INC. -- EXHIBIT 2012 0012
`
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`

`
`UNITED STATES DEPARTMENT OF COMMERCE
`U.S. Patent and Trademark Office
`Address : COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`
`APPLICATION NO./
`CONTROL NO.
`13/719,379
`
`FILING DATE
`
`19 December, 2012
`
`FIRST NAMED INVENTOR /
`PATENT IN REEXAMINATION
`BRITTAIN ET AL. (cid:9)
`
`ATTORNEY DOCKET NO.
`
`CEPH-4457/CP391B US
`
`WOODCOCK WASHBURN LLP
`
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`EXAMINER
`
`RICHARD ELLIS
`
`ART UNIT
`
`PAPER
`
`OPIM
`
`A-82087
`
`DATE MAILED:
`
`Please find below and/or attached an Office communication concerning this application or
`proceeding.
`
`The attached addendum forms part of the previously mailed PTOL-85 (Notice of Allowance and Fees Due). This addendum does
`NOT change the time period set in the PTOL-85 for payment of the issue fee.
`
`ANY QUESTIONS REGARDING THIS COMMUNICATION SHOULD BE DIRECIED TO THE OFFICE OF PATENT LEGAL
`ADMINISTRATION AT (571) 272-7701.
`
`Commissioner for Patents
`
`PTO-90C (Rev.04-03)
`
`0013
`
`CEPHALON, INC. -- EXHIBIT 2012 0013
`
`(cid:9)
`(cid:9)
`

`
`Notices of Allowance and Fee(s) Due mailed between October 1, 2013 and
`December 31, 2013
`
`(Addendum to PTOL-85)
`
`If the "Notice of Allowance and Fee(s) Due" has a mailing date on or after October 1, 2013 and before
`January 1, 2014, the following information is applicable to this application.
`
`If the issue fee is being timely paid on or after January 1, 2014, the amount due is the issue fee and
`publication fee in effect January 1, 2014. On January 1, 2014, the issue fees set forth in 37 CFR 1.18
`decrease significantly and the publication fee set forth in 37 CFR 1.18(d)(1) decreases to $0.
`
`If an issue fee or publication fee has been previously paid in this application, applicant is not entitled to a
`refund of the difference between the amount paid and the amount in effect on January 1, 2014.
`
`0014
`
`CEPHALON, INC. -- EXHIBIT 2012 0014
`
`

`
`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or Fax (571)-273-2885
`
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where
`appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for
`maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)
`
`10/02/2013
`7590 (cid:9)
`46347 (cid:9)
`WOODCOCK WASHBURN LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`Note: A certificate of mailing can only be used for domestic mailings of the
`Fee(s) Transmittal. This certificate cannot be used for any other accompanying
`papers. Each additional paper, such as an assignment or formal drawing, must
`have its own certificate of mailing or transmission.
`
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`States Postal Service with sufficient postage for first class mail in an envelope
`addressed to the Mail Stop ISSUE FEE address above, or being facsimile
`transmitted to the USPTO (571) 273-2885, on the date indicated below.
`
`(Depositor's name)
`
`(Signature)
`
`(Date)
`
`APPLICATION NO. (cid:9)
`
`13/719,379 (cid:9)
`
`FILING DATE
`
`12/19/2012 (cid:9)
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO. (cid:9)
`
`CONFIRMATION NO.
`
`Jason Edward Brittain
`
`CEPH-4457/CP391B US
`
`6187
`
`TITLE OF INVENTION: BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE (cid:9)
`
`I PUBLICATION FEE DUE PREY. PAID ISSUE FEE TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$1780
`
`$0
`
`$0
`
`$1780
`
`01/02/2014
`
`EXAMINER
`
`SOROUSH, ALI
`
`ART UNIT
`
`CLASS-SUBCLASS
`
`1617
`
`548-304700
`
`1. Change of correspondence address or indication of "Fee Address" (37
`CFR 1.363).
`q Change of correspondence address (or Change of Correspondence
`Address form PTO/SB/122) attached.
`q "Fee Address" indication (or "Fee Address" Indication form
`PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer
`Number is required.
`
`2. For printing on the patent front page, list
`(1) the names of up to 3 registered patent attorneys
`or agents OR, alternatively,
`(2) the name of a single firm (having as a member a
`registered attorney or agent) and the names of up to
`2 registered patent attorneys or agents. If no name is
`listed, no name will be printed.
`
`1 Woodcock Washburn LLP
`
`2 (cid:9)
`
`3 (cid:9)
`
`
`
`
`
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for
`recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAME OF ASSIGNEE (cid:9)
`(B) RESIDENCE: (CITY and STATE OR COUNTRY)
`
`Cephalon, Inc. (cid:9)
`
`Frazer, Pennsylvania
`
`Please check the appropriate assignee category or categories (will not be printed on the patent) :
`
`q Individual a Corporation or other private group entity
`
`q Government
`
`4a. The following fee(s) are submitted:
`
`a Issue Fee
`
`q Publication Fee (No small entity discount permitted)
`q Advance Order - # of Copies (cid:9)
`
`
`
`4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)
`q A check is enclosed.
`q Payment by credit card. Form PTO-2038 is attached.
`3 The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any
`overpayment, to Deposit Account Number 733050
`(cid:9) (enclose an extra copy of this form).
`
`PTOL-85 (Rev. 02/11)
`
`Page 2 of 4
`
`0015
`
`CEPHALON, INC. -- EXHIBIT 2012 0015
`
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`

`
`5. Change in Entity Status (from status indicated above)
`q Applicant certifying micro entity status. See 37 CFR 1.29
`
`q Applicant asserting small entity status. See 37 CFR 1.27
`
`q Applicant changing to regular undiscounted fee status.
`
`NOTE: Absent a valid certification of Micro Entity Status (see form PTO/SB/15A and 15B), issue
`fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
`NOTE: If the application was previously under micro entity status, checking this box will be taken
`to be a notification of loss of entitlement to micro entity status.
`NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro
`entity status, as applicable.
`
`NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in
`interest as shown by the records of the United States Patent and Trademark Office.
`
`Authorized Signature
`
`/Stephanie A. Lodise/ (cid:9)
`
`Typed or printed name (cid:9)
`
`Stephanie A. Lodise
`
`November 5, 2013
`
`Date (cid:9)
`
`
`
`Registration No. (cid:9)
`
`51430
`
`
`
`
`
`This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process)
`an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and
`submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete
`this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O.
`Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450,
`Alexandria, Virginia 22313-1450.
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`PTOL-85 (Rev. 02/11) Approved for use through 08/31/2013. (cid:9)
`
`OMB 0651-0033 (cid:9)
`
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`Page 3 of 4
`
`0016
`
`CEPHALON, INC. -- EXHIBIT 2012 0016
`
`(cid:9)
`

`
`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`13719379
`
`19-Dec-2012
`
`Title of Invention:
`
`BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`First Named Inventor/Applicant Name:
`
`Jason Edward Brittain
`
`Filer:
`
`Stephanie A. Lodise/Danielle Langdon
`
`Attorney Docket Number:
`
`CEPH-4457/CP391 B US
`
`Filed as Large Entity
`
`Utility under 35 USC 111(a) Filing Fees
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Basic Filing:
`
`Pages:
`
`Claims:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`Utility Appl Issue Fee
`
`1501
`
`1
`
`1780
`
`1780
`
`Extension-of-Time:
`
`0017
`
`CEPHALON, INC. -- EXHIBIT 2012 0017
`
`

`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Miscellaneous:
`
`Total in USD ($)
`
`1780
`
`0018
`
`CEPHALON, INC. -- EXHIBIT 2012 0018
`
`

`
`Electronic Acknowledgement Receipt
`
`EFS ID:
`
`Application Number:
`
`17318914
`
`13719379
`
`International Application Number:
`
`Confirmation Number:
`
`6187
`
`Title of Invention:
`
`BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`First Named Inventor/Applicant Name:
`
`Jason Edward Brittain
`
`Customer Number:
`
`46347
`
`Filer:
`
`Stephanie A. Lodise/Danielle Langdon
`
`Filer Authorized By:
`
`Stephanie A. Lodise
`
`Attorney Docket Number:
`
`CEPH-4457/CP391 B US
`
`Receipt Date:
`
`Filing Date:
`
`05-NOV-2013
`
`19-DEC-2012
`
`Time Stamp:
`
`15:19:30
`
`Application Type:
`
`Utility under 35 USC 111(a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`RAM confirmation Number
`
`Deposit Account
`
`Authorized User
`
`yes
`
`Deposit Account
`
`$1780
`
`1905
`
`233050
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)
`
`0019
`
`CEPHALON, INC. -- EXHIBIT 2012 0019
`
`

`
`Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)
`
`File Listing:
`
`Docum